Sponsor	Phase
Radboud University Medical Center	Phase 2
United States Department of Defense	Phase 2
Novartis Pharmaceuticals	Phase 2

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LAMPRENE	clofazimine	CAPSULE;ORAL	019500-002	Dec 15, 1986		DISCN	Yes	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Novartis	LAMPRENE	clofazimine	CAPSULE;ORAL	019500-001	Dec 15, 1986		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: August 10, 2026

Lamprene (clofazimine) is a mature, low-revenue anti-infective with limited commercial growth potential but persistent public-health demand. Its market is shaped by leprosy control programs, WHO procurement, donation arrangements, and off-label use against nontuberculous mycobacterial infections. The product has little meaningful patent protection, no biosimilar exposure, and limited public product-level financial disclosure. Its main risks are supply concentration, regulatory access, low-volume manufacturing, and resistance management rather than generic patent litigation.

Lamprene Clofazimine Market Dynamics and Financial Trajectory

What is Lamprene and how is clofazimine used?

Lamprene is the brand name for clofazimine, a riminophenazine antimicrobial developed for the treatment of leprosy. The U.S. Food and Drug Administration approved Lamprene capsules in 1986 for lepromatous leprosy, including erythema nodosum leprosum, a severe inflammatory complication of the disease [1].

Clofazimine is used primarily in multidrug therapy with rifampicin and dapsone. The World Health Organization includes clofazimine in its recommended multidrug regimen for multibacillary leprosy and supplies it through global leprosy-control programs [2].

The drug also has clinical use outside its original indication. Physicians use clofazimine in some treatment regimens for Mycobacterium avium complex and other nontuberculous mycobacterial infections. These applications are generally off label and are not equivalent to FDA-approved indications.

Attribute	Lamprene / clofazimine
Active ingredient	Clofazimine
Drug class	Riminophenazine antimicrobial
Original indication	Lepromatous leprosy
U.S. dosage form	50 mg and 100 mg capsules
FDA approval	1986
Primary global use	WHO multidrug therapy for leprosy
Major off-label use	Nontuberculous mycobacterial infections
Biosimilar exposure	None
Patent posture	Mature molecule with limited apparent blocking protection
Commercial model	Public procurement, specialized distribution, and limited branded sales

How large is the Lamprene and clofazimine market?

The commercial market is small compared with markets for antibiotics used in common bacterial infections. Leprosy is a neglected disease with a limited global patient population, and clofazimine is administered as part of a low-cost multidrug regimen.

WHO reported approximately 170,000 new leprosy cases globally in 2022, with the largest case burdens concentrated in India, Brazil, Indonesia and several countries in Africa and Southeast Asia [3]. Annual case incidence has remained materially below the levels observed for high-volume infectious diseases.

Market demand has two distinct components:

Public-health procurement for leprosy.
Hospital and specialist demand for off-label nontuberculous mycobacterial treatment.

The leprosy segment is relatively stable but price constrained. Procurement often occurs through governments, international agencies and donor-supported programs. The off-label segment can command higher prices in markets where clofazimine is difficult to obtain, but volumes remain limited and regulatory access varies by country.

No reliable public source reports standalone Lamprene revenue. Novartis, the historical commercial sponsor, reports financial results at business-unit and group levels rather than disclosing Lamprene sales. The absence of product-level revenue data prevents a credible calculation of annual Lamprene revenue, market share or compound annual growth rate.

What is the financial trajectory for Lamprene?

Lamprene’s financial trajectory is best characterized as mature, low-growth and supply-driven.

Historical commercial phase

Lamprene entered the market as a branded orphan or specialty anti-infective. Its commercial opportunity was limited from the start because leprosy prevalence was low, treatment courses were controlled by public-health programs, and the drug was used in combination therapy rather than as a high-value proprietary monotherapy.

The commercial value of the product was also constrained by the absence of a broad private-pay market. Most demand came from institutional purchasers rather than retail patients.

Mature and donation-supported phase

Clofazimine later became closely associated with WHO-supported leprosy programs. Novartis has participated in global leprosy initiatives, including product donations and supply arrangements. These programs reduce the addressable commercial revenue available to the originator while maintaining the drug’s public-health presence [4].

The result is a product with continuing clinical relevance but limited revenue expansion. Unit demand is linked more closely to leprosy-control funding, diagnosis rates, treatment completion and supply contracts than to conventional pharmaceutical promotion.

Off-label demand phase

Interest in clofazimine has increased in specialist infectious-disease practice because of its activity against certain nontuberculous mycobacteria. The drug is used in some multidrug regimens for refractory or difficult-to-treat disease.

This use creates potential demand growth, but it does not produce the financial profile of a newly approved indication. The principal constraints are:

Off-label prescribing.
Variable reimbursement.
Limited clinical-trial evidence in some settings.
Cardiac QT-interval concerns.
Skin discoloration and other tolerability issues.
Competition from other antimycobacterial agents.
Small specialist-prescriber base.

Clofazimine therefore has a structurally limited revenue ceiling. Growth from nontuberculous mycobacterial use may support demand, but it is unlikely to transform Lamprene into a major commercial product without a new branded formulation or approved indication.

What is the Orange Book status of Lamprene?

Lamprene was approved by FDA under NDA 019500, according to the FDA prescribing information and product records [1]. Publicly available FDA materials do not indicate a meaningful current patent barrier protecting the active ingredient.

The relevant commercial issue is not a conventional Orange Book patent cliff. Clofazimine was discovered decades ago, and the core compound patent estate has long passed its ordinary enforceable term. Any remaining protection would need to arise from later patents covering formulations, manufacturing processes, combinations or specific methods of use.

No widely recognized active Lamprene patent estate appears to create a substantial U.S. barrier to generic or alternative-source development. The practical obstacles are more likely to involve regulatory status, product availability, clinical demand and manufacturing economics.

When does Lamprene lose exclusivity?

Lamprene’s principal exclusivity period expired many years ago. The original FDA approval dates to 1986, and any ordinary small-molecule regulatory exclusivity associated with that approval has expired.

Exclusivity category	Lamprene status
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	No current exclusivity identified for the original product
Core compound patent	Expired based on the age of the molecule
Formulation patents	No widely recognized blocking estate identified
Method-of-use patents	No widely recognized blocking estate identified
Biosimilar exclusivity	Not applicable
Current commercial protection	Primarily regulatory, supply-chain and market-access factors

The absence of active exclusivity does not guarantee immediate generic entry. A potential entrant must still establish an acceptable product, obtain regulatory approval, secure API supply and justify the economics of a small-volume market.

How many patents cover Lamprene and clofazimine?

The commercially important patent estate is limited. Clofazimine patents may appear in patent databases because of historical filings, later formulations, combinations or research uses. Those records should not be confused with live patents that block sale of the original capsule product.

The main patent categories are:

Patent category	Commercial relevance
Original clofazimine compound patents	Generally expired
Capsule formulations	Potentially relevant if a later formulation remains enforceable
Combination therapy	May cover specific combinations or dosing methods, but usually does not block the molecule itself
Nontuberculous mycobacterial treatment methods	Potentially relevant to branded follow-on products
Manufacturing processes	May create process-specific barriers but rarely establish broad market exclusivity
Salt, crystal or delivery-system patents	Could matter for a reformulated product

A company seeking to commercialize a conventional clofazimine capsule would likely face a freedom-to-operate analysis focused on formulation and manufacturing claims rather than the original active ingredient.

Which companies manufacture or supply clofazimine?

Novartis is the historical originator and brand-associated company for Lamprene. The global supply structure also includes public-health purchasers, contract manufacturers and regional pharmaceutical suppliers.

The competitive landscape is fragmented because commercial availability differs by jurisdiction. In some countries, clofazimine is supplied through national leprosy programs. In others, hospitals obtain it through specialized channels. In the United States, access has historically been more constrained than access to many standard generic antibiotics.

The market has three broad supplier types:

Originator-linked supply associated with Lamprene.
Public-health and donor-supported supply.
Generic or regional manufacturers serving jurisdictions where clofazimine is registered.

A generic entrant would compete on regulatory access, quality consistency, supply reliability and procurement eligibility. Price alone may not determine success because the market is small and buyers place high value on dependable delivery.

Are there Paragraph IV challenges or generic litigation involving Lamprene?

No prominent, commercially material Paragraph IV campaign involving Lamprene is widely reported. The product’s age and limited market size reduce the incentive for high-cost patent litigation.

A potential generic applicant would have little reason to challenge an active compound patent if the relevant patents have expired. Litigation risk would instead arise from:

A later-listed formulation patent.
A method-of-use patent.
Manufacturing or process claims.
Product liability allegations.
Distribution or procurement disputes.
Regulatory exclusivity tied to a newly developed formulation.

The lack of major Paragraph IV activity is consistent with the drug’s low revenue opportunity and weak apparent patent position.

What formulation patents protect Lamprene?

The original product is an oral capsule containing clofazimine. Its commercial differentiation is limited. The formulation has historically been associated with gastrointestinal tolerability and absorption considerations, but no widely recognized, high-value formulation patent currently defines the market.

Potential follow-on opportunities include:

Improved bioavailability.
Reduced gastrointestinal irritation.
Lower discoloration burden.
Modified-release delivery.
Pediatric formulations.
Fixed-dose combinations with other leprosy medicines.
Alternative delivery systems for nontuberculous mycobacterial disease.

A new formulation could obtain patent protection if it produces a defensible technical benefit and satisfies patentability requirements. It would still need clinical and regulatory development, and the commercial opportunity would depend on reimbursement and adoption.

What regulatory issues affect the Lamprene market?

Regulatory status is a major market variable. Clofazimine has an FDA-approved legacy indication, but availability can be limited even when the active ingredient is well established.

Key regulatory factors include:

Whether a supplier has an approved U.S. product.
Whether the product is actively marketed.
Whether a hospital can obtain supply through a special-access route.
Whether a generic applicant can demonstrate bioequivalence.
Whether a new indication requires clinical evidence.
Whether pharmacovigilance requirements address QT prolongation and other risks.

Clofazimine can cause skin discoloration, gastrointestinal effects and cardiac conduction concerns, particularly when combined with other QT-prolonging medicines. These issues influence prescribing, label design and regulatory development strategy [1].

What manufacturing and intellectual-property barriers exist?

The intellectual-property barrier is relatively low for the conventional molecule. Manufacturing and commercial barriers are higher.

A supplier must maintain:

Qualified clofazimine API production.
Consistent particle and dissolution characteristics.
Capsule stability.
Validated impurity controls.
Reliable global logistics.
Registration in target markets.
Procurement eligibility for public-health programs.

Because the market is small, manufacturers may face weak economies of scale. A single production interruption can have a disproportionate effect on availability. This creates a market in which supply resilience may be more valuable than marginal price reductions.

How does Lamprene compare with competing leprosy drugs?

Clofazimine is part of a combination regimen rather than a stand-alone competitor to rifampicin or dapsone.

Drug	Role in leprosy therapy	Market position	Patent risk
Clofazimine	Core component of multibacillary therapy	Low-volume, public-health driven	Low
Rifampicin	Highly active bactericidal component	Broad generic market	Low
Dapsone	Core component of multidrug therapy	Broad generic market	Low
Minocycline	Alternative or specialist use	Limited	Low
Ofloxacin	Alternative in selected regimens	Generic	Low

Clofazimine’s differentiation is its role in multidrug therapy and activity against certain mycobacterial infections. It does not have a conventional premium-positioning advantage in leprosy.

What generic launch scenarios exist for Lamprene?

The most credible launch scenario is a regional or specialty generic product targeting markets with persistent leprosy demand or nontuberculous mycobacterial use.

Scenario	Probability driver	Financial outcome
Public-health generic launch	Government or WHO procurement	Low margin, recurring volume
U.S. specialty generic launch	Regulatory approval and access improvement	Potentially higher price, limited volume
Reformulated product	Improved tolerability or dosing	Higher development cost, greater pricing potential
Fixed-dose combination	Simplified leprosy treatment	Procurement and regulatory complexity
No new entrant	Weak market economics	Continued supply concentration

A generic launch would not necessarily produce rapid erosion of Lamprene demand because originator sales are already limited and the market may include supply gaps rather than a large branded base.

What is the investment outlook for Lamprene?

Lamprene is not a conventional growth asset. Its investment value lies in strategic access, supply reliability and potential lifecycle development rather than in branded sales growth.

The most relevant value drivers are:

Expansion of diagnosed nontuberculous mycobacterial disease.
Development of a better-tolerated formulation.
Long-term public-health procurement.
Regional registration in underserved markets.
Fixed-dose combination development.
Contract manufacturing or specialty distribution.

The principal downside risks are low pricing, limited volume, regulatory friction, adverse-effect concerns and substitution by alternative antimycobacterial drugs.

Key Takeaways

Lamprene is the branded form of clofazimine, an established riminophenazine antimicrobial.
Its principal approved use is lepromatous leprosy within multidrug therapy.
The commercial market is small and is driven by public-health procurement and specialist off-label use.
Novartis does not publicly disclose standalone Lamprene revenue, preventing a reliable product-level financial forecast.
Core molecule exclusivity has expired, and no major active blocking patent estate is widely recognized.
Paragraph IV and patent-litigation activity appear limited because the market does not justify substantial litigation costs.
Generic entry risk is technically credible but commercially constrained by low volume, regulatory access and manufacturing economics.
The strongest commercial opportunity is a reformulated or combination product addressing tolerability, dosing or access.
Biosimilar risk is irrelevant because clofazimine is a chemically synthesized small molecule.
Supply-chain resilience is more important than conventional patent protection in determining market position.

FAQs

Is Lamprene still commercially available in the United States?

Availability has historically been constrained relative to standard generic antibiotics. U.S. access depends on the status of the marketed product, authorized suppliers and applicable FDA access mechanisms.

Is clofazimine used for tuberculosis?

Clofazimine is not a standard first-line treatment for drug-susceptible tuberculosis. It may be considered in selected drug-resistant or nontuberculous mycobacterial regimens under specialist supervision.

Does clofazimine have generic competition?

Generic or alternative-source availability varies by country. The absence of core patent protection supports potential generic competition, but regulatory registration and limited market economics restrict the number of suppliers.

Can a new company patent a clofazimine product?

A company generally cannot obtain a new patent on the old molecule itself. It may pursue patents for a novel formulation, delivery system, combination, manufacturing process or treatment method if the claims satisfy applicable patentability standards.

What is the principal commercial risk for Lamprene?

The principal risk is not patent expiry. It is limited demand combined with supply concentration, procurement dependence, regulatory access constraints and tolerability concerns.

References

U.S. Food and Drug Administration. (2019). Lamprene (clofazimine) capsules prescribing information. FDA.
World Health Organization. (2018). Guidelines for the diagnosis, treatment and prevention of leprosy. WHO.
World Health Organization. (2023). Global leprosy update, 2022: New cases detected worldwide. Weekly Epidemiological Record.
Novartis. (2023). Annual report 2022. Novartis AG.

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	12
What excipients (inactive ingredients) are in LAMPRENE?	LAMPRENE excipients list
DailyMed Link:	LAMPRENE at DailyMed

LAMPRENE Drug Patent Profile

When do Lamprene patents expire, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for LAMPRENE

Recent Clinical Trials for LAMPRENE

Pharmacology for LAMPRENE

US Patents and Regulatory Information for LAMPRENE